Manipal AcuNova Ltd, the first Indian CRO to be certified with 3 ISO certifications, today announced the receipt of the prestigious Frost & Sullivan's 'Partner of Choice' award for bioavailability and bioequivalence studies.
Frost & Sullivan team visited Manipal AcuNova research centre at Bangalore, Mangalore and Manipal to evaluate on criteria of technical know-how of the personnel involved, value-added services to the customers compared to the competitors in the industry, quality initiatives, responsiveness of the service provider and significance of the technology in the industry.
According to D A Prasanna, vice chairman and managing director, Manipal AcuNova, India has emerged as a key destination for conducting clinical research. "We are benchmarked by Frost & Sullivan as the "Partner of Choice" in a field where there are several Indian players. This award is an assurance of global quality to our clients. Our strategy of differentiating ourselves on quality parameters has qualified us to this prestigious position," he added.
The award acknowledges the best life science companies in India that have achieved and sustained excellence in their industry value chain with commending diligence, commitment and innovative business strategies required to advance in the global marketplace. The companies are evaluated by rigorous analysis of specific criteria in a variety of regional and global markets that exhibit superiority in planning and execution of product launches, strategic alliances, distribution strategies, technological innovations, customer service, mergers & acquisitions and a host of other crucial marketing factors such as leadership, strategy, service, innovation, integration and development.
Manipal AcuNova conducts bioavailability, bioequivalence and PK/PD studies at its centers in compliance with international regulatory requirements. Studies are monitored by an independent quality assurance department. The centre is located at Manipal, India, with a 36-bed clinical pharmacology unit (CPU) with an integrated clinical testing and bio-analytical laboratory.
Manipal AcuNova Ltd is a single source provider of clinical research bio availability and bio equivalence, phase I - IV clinical trials, clinical data management and the central lab. Manipal AcuNova has access to the India's largest integrated hospital network that caters to over 1.5 million patients annually. Manipal AcuNova has the distinction of being selected as the CRO by the Department of Biotechnology, government of India for its funded studies and by Indian and global pharma companies. Currently over 45 studies have been completed and filed the data with FDA, EU and other regulators.
It has also been awarded as 'India's No 1 emerging CRO' in 2005 by Proximare Inc, a New Jersey based strategic consulting firm.